rasagiline mesylate tablet
alvogen, inc. - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline 0.5 mg - rasagiline mesylate tablets are indicated for the treatment of parkinson’s disease (pd). rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)]. at least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with these medications. rasagiline is contraindicated for use with st. john’s wort and with cyclobenzaprine. rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. pregnancy category c there are no adequate and well-controlled studies of rasagiline in pregnant women. rasagiline should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in a combined mating/fertility and embryo-fetal development study in pregnant rats, no effect on embryo-fetal development was observed at oral doses
rasagiline mesylate tablet
mylan pharmaceuticals inc. - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline 0.5 mg - rasagiline tablets are indicated for the treatment of parkinson’s disease (pd). rasagiline tablets are contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)] . at least 14 days should elapse between discontinuation of rasagiline tablets and initiation of treatment with these medications. rasagiline tablets are contraindicated for use with st. john’s wort and with cyclobenzaprine. rasagiline tablets are contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. there are no adequate data on the developmental risks associated with the use of rasagiline in pregnant women. in animal studies, oral administration of rasagiline to rats during gestation and lactation resulted in decreased survival and reduced body weight in the offspring at doses similar to those used clinically. when administered to preg
teva-rasagiline tablet
teva canada limited - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors
teva-rasagiline tablet
teva canada limited - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors
apo-rasagiline tablet
apotex inc - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors
apo-rasagiline tablet
apotex inc - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors
ag-rasagiline tablet
angita pharma inc. - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors
ag-rasagiline tablet
angita pharma inc. - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors
mint-rasagiline tablet
mint pharmaceuticals inc - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg
mint-rasagiline tablet
mint pharmaceuticals inc - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg